#United States #Washington, D.C. #obesity #Novo Nordisk #CagriSema

CagriSema Breakthrough in Obesity Treatment

Novo Nordisk recently announced the impressive findings from the phase 3 REDEFINE 9 trial, which focused on its investigational drug CagriSema. This innovative treatment combines a GLP-1 receptor agonist with an amylin analog and has shown remarkable results in weight loss among participants diagnosed with obesity. The trial's results, which were also presented at ObesityWeek® 2026, highlight an average weight reduction of approximately 21%, showcasing the potential effectiveness of CagriSema in the fight against obesity.

Trial Overview

The REDEFINE 9 trial was a rigorous and comprehensive study that evaluated the efficacy and safety of two lower doses of CagriSema—1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg. Over a period of 68 weeks, the trial enrolled 309 adults, all suffering from obesity or being overweight with accompanying complications, but none were diagnosed with diabetes. The trial’s designs ensured robust comparisons against a placebo group, leading to significant findings.

In terms of weight loss, participants undergoing treatment with CagriSema 1.7 mg / 1.7 mg lost an average of 20.7%, while those on the 1.0 mg / 1.0 mg dosage saw an average weight loss of 21.0%. In stark contrast, only a mere 2% weight loss was observed in the placebo group, clearly demonstrating the efficacy of the drug compared to a non-active treatment. This data made a strong case for the potential clinical use of CagriSema in obesity management.

Significance of Findings

Martin Holst Lange, Novo Nordisk’s executive vice president and chief scientific officer, emphasized the importance of understanding different treatment responses across doses. The trial not only evaluated the effectiveness of CagriSema but also contributed invaluable data about dose variations. “These findings support our continued efforts to explore and develop the combination of cagrilintide and semaglutide for those struggling with obesity,” Lange stated.

Beyond average weight loss, the trial also demonstrated that CagriSema at both tested doses significantly assisted patients in achieving substantial body weight reductions, with a noteworthy percentage able to lose at least 5%, 10%, 15%, and even 20% of their starting weight. The corresponding improvements in waist circumference further highlighted the drug’s effectiveness in reducing abdominal fat, a defining characteristic of obesity.

Safety Profile

Safety considerations are paramount in any clinical trial, and REDEFINE 9 was no different. The safety data collected aligned with prior studies on CagriSema, primarily indicating gastrointestinal adverse events that were mostly mild to moderate in severity. Specifically, treatment discontinuation due to adverse events was reported in 2.9% of participants on the higher dose and 4.9% on the lower dose, compared to 4.9% in the placebo group—indicating that the drug has a manageable safety profile.

Dr. Sean Wharton from the University of Toronto, who led the REDEFINE 9 publication, reinforced the significance of these findings, indicating a clear gap between CagriSema and placebo treatment outcomes. “These results provide crucial evidence to guide clinicians in making tailored dosing decisions based on patient needs, ultimately enhancing treatment experiences,” Dr. Wharton noted.

Future Directions

In December 2025, Novo Nordisk submitted a New Drug Application to the U.S. Food and Drug Administration for the use of CagriSema at the maximum tested dose of 2.4 mg / 2.4 mg for weight management. Regulatory decisions regarding the availability and clinical application of CagriSema are eagerly awaited, expected in the fourth quarter of 2026.

As obesity continues to pose significant health risks globally, the innovation brought by CagriSema could herald a new era in obesity treatment—a multi-faceted solution that addresses not just weight loss, but the complexities associated with obesity itself.

In summary, the REDEFINE 9 trial results signal a promising step forward for obesity treatment, illustrating the potential of CagriSema. With its impressive weight loss outcomes and positive safety profile, stakeholders are optimistic about its eventual approval and the significantly positive impact it could have on millions struggling with obesity. As we await regulatory decisions, the scientific community is optimistic and keen to explore this new horizon in obesity management further.